Is SMS Pharmaceuticals a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that SMS Pharmaceuticals Ltd is a below average quality company .

Is SMS Pharmaceuticals undervalued or overvalued?

The key valuation ratios of SMS Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is SMS Pharmaceuticals share price return in the past 10 years?

SMS Pharmaceuticals Ltd share price has appreciated 23.8% annually (CAGR) over the past ten years.

Is SMS Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of SMS Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

SMS Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: SMS Pharmaceuticals
Brand: SMS Pharmaceuticals

BSE: 532815 | NSE: SMSPHARMA | Pharmaceuticals & Drugs | Small Cap

Place order

SMS Pharmaceuticals Share Price

₹207.50 -1.15 -0.55%
as on 18-Apr'24 12:35

10 Year X-Ray of SMS Pharmaceuticals:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	7.8%	11.7%	11.6%	10.2%	11.8%	10.6%	8%	11.4%	11.1%	2.2%	-
Value Creation Index ⓘ	-0.5	-0.2	-0.2	-0.3	-0.2	-0.3	-0.4	-0.2	-0.2	-0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	525	587	612	445	465	465	412	563	520	522	613
Sales YoY Gr.	-	11.8%	4.3%	-27.2%	4.4%	0%	-11.4%	36.7%	-7.7%	0.4%	-
Adj EPS ⓘ	2.4	4.1	4.9	4.2	4.7	4.8	3.7	7.2	7.8	0.2	4.9
YoY Gr.	-	68.7%	19%	-14.6%	13.2%	2.1%	-22.8%	92.5%	9.2%	-97.8%	-
BVPS (₹) ⓘ	26.2	30.1	34.8	31	35.6	40.2	43.4	50.6	58.3	58.5	62.1
Adj Net Profit ⓘ	20.6	34.7	41.3	35.3	39.9	40.8	31.5	60.6	66.2	1.4	42
Cash Flow from Ops. ⓘ	65.1	58.7	61.2	73.5	31.8	49.8	39.7	90.5	45.1	22.5	-
Debt/CF from Ops. ⓘ	2.6	2.8	3.3	2	4.6	2.9	3.8	2.8	5.8	11.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-0.1%	2.3%	8.2%	0.4%
Adj EPS ⓘ	-25.6%	-48.6%	-64.3%	-97.8%
BVPSⓘ	9.3%	10.5%	10.5%	0.3%
Share Price	23.8%	27%	13.9%	183.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	8.8	14.6	15	12.7	14.2	12.7	8.9	15.2	14.4	0.3	8.1
Op. Profit Mgn % ⓘ	11	14.7	14.6	16.9	20.1	19.4	19.4	21.5	22.1	10.5	17.4
Net Profit Mgn % ⓘ	3.9	5.9	6.8	7.9	8.6	8.8	7.6	10.8	12.7	0.3	6.8
Debt to Equity ⓘ	0.8	0.7	0.7	0.6	0.5	0.4	0.4	0.6	0.5	0.5	-
Working Cap Days ⓘ	126	128	131	160	128	152	198	167	215	256	129
Cash Conv. Cycle ⓘ	57	46	43	44	43	67	91	82	123	149	45

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.51

Sales growth is good in last 4 quarters at 67.13%

Return on Equity has declined versus last 3 years average to 8.10%

Sales growth has been subdued in last 3 years 8.22%

Net Profit has been subdued in last 3 years -64.25%

Latest Financials - SMS Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	4.9	4.6
TTM Sales (₹ Cr.)	613	613
BVPS (₹.) ⓘ	62.1	58
Reserves (₹ Cr.) ⓘ	517	483
P/BV ⓘ	3.36	3.60
PE ⓘ	42.48	45.56

From the Market
52 Week Low / High (₹)	65.00 / 217.60
All Time Low / High (₹)	7.21 / 217.60
Market Cap (₹ Cr.)	1,766
Equity (₹ Cr.)	8.5
Face Value (₹)	1
Industry PE ⓘ	47.8

Management X-Ray of SMS Pharmaceuticals:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

10.24

10.73

10.71

19.51

19.40

* Pledged shares as % of Promoter's holding (%)

Valuation of SMS Pharmaceuticals

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of SMS Pharmaceuticals

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	525	587	612	445	465	465	412	563	520	522
Operating Expenses ⓘ	468	500	522	370	372	375	332	442	405	467
Manufacturing Costs	50	58	72	29	35	35	34	40	58	59
Material Costs	364	382	385	296	290	293	246	340	275	336
Employee Cost	26	32	38	27	33	36	39	41	51	55
Other Costs ⓘ	27	29	27	19	14	11	12	21	20	18
Operating Profit ⓘ	57	86	89	75	93	90	80	121	115	55
Operating Profit Margin (%)	10.9%	14.7%	14.6%	16.9%	20.1%	19.4%	19.4%	21.5%	22.1%	10.5%
Other Income ⓘ	2	16	4	1	2	3	5	3	5	5
Interest ⓘ	14	18	17	16	15	12	12	11	19	22
Depreciation ⓘ	13	17	19	19	20	19	22	22	32	32
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	32	67	56	42	60	62	51	91	69	6
Tax ⓘ	12	32	15	6	20	21	18	30	1	1
Profit After Tax	20	35	42	36	40	41	33	61	68	4
PAT Margin (%)	3.9%	6.0%	6.8%	8.0%	8.7%	8.9%	7.9%	10.8%	13.1%	0.8%
Adjusted EPS (₹)	2.4	4.2	4.9	4.2	4.8	4.9	3.9	7.2	8.0	0.5
Dividend Payout Ratio (%)	8%	5%	4%	5%	5%	5%	6%	4%	4%	62%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	222	255	294	263	301	340	367	428	494	495
Share Capital ⓘ	8	8	8	8	8	8	8	8	8	8
Reserves ⓘ	213	246	286	254	293	331	359	420	485	487
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	150	152	186	134	130	133	129	218	217	215
Long Term Debt	69	82	113	74	71	62	68	147	150	121
Short Term Debt	80	70	73	60	58	71	61	71	68	94
Trade Payables	59	61	84	67	39	48	44	65	73	113
Others Liabilities ⓘ	79	73	92	47	62	70	95	134	114	91
Total Liabilities ⓘ	509	540	656	510	532	590	636	846	898	914
Fixed Assets
Gross Block	342	388	433	310	318	340	361	559	570	576
Accumulated Depreciation	95	112	63	19	39	58	80	101	132	164
Net Fixed Assetsⓘ	247	277	370	290	279	281	280	457	438	412
CWIP ⓘ	39	29	13	8	8	18	42	7	11	33
Investmentsⓘ	6	13	21	37	45	45	45	45	45	45
Inventories	90	86	113	93	107	136	129	138	251	223
Trade Receivables	56	59	61	21	24	26	49	106	49	148
Cash Equivalents	12	6	15	12	13	15	10	41	47	7
Others Assetsⓘ	59	69	63	49	55	68	81	53	58	45
Total Assets ⓘ	509	540	656	510	532	590	636	846	898	914

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	65	59	61	73	32	50	40	90	45	22
PBT ⓘ	32	67	56	42	60	62	51	91	69	6
Adjustment ⓘ	19	27	28	32	31	27	29	28	50	53
Changes in Working Capital ⓘ	15	-29	-1	9	-48	-26	-28	-12	-58	-31
Tax Paid ⓘ	-1	-6	-22	-9	-11	-13	-12	-16	-15	-5
Cash Flow From Investing Activity ⓘ	-37	-55	-97	-39	-17	-35	-43	-152	-27	-30
Capex	-54	-48	-89	-23	-9	-35	-43	-152	-27	-30
Net Investments	-6	-7	-8	-16	-8	0	0	0	0	0
Others ⓘ	23	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activityⓘ	-30	-10	44	-33	-15	-13	-2	92	-12	-32
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	15	11	35	-11	-2	-15	18	88	12	-34
Interest Paid ⓘ	-5	-8	-8	-12	-10	-8	-6	-6	-18	-21
Dividend Paid ⓘ	-2	-2	-2	-2	-2	-3	-4	0	-3	-3
Others ⓘ	-39	-12	20	-8	-1	12	-11	10	-4	25
Net Cash Flow ⓘ	-2	-6	9	1	0	2	-5	31	6	-39

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	8.75	14.79	15.17	12.79	14.35	12.93	9.24	15.32	14.76	0.83
ROCE (%)	11.75	21.08	15.95	12.61	17.66	15.96	12.57	17.07	12.26	3.67
Asset Turnover Ratio	1.1	1.15	1.05	0.78	0.96	0.9	0.74	0.82	0.64	0.61
PAT to CFO Conversion(x)	3.25	1.69	1.45	2.03	0.8	1.22	1.21	1.48	0.66	5.5
Working Capital Days
Receivable Days	31	35	35	33	17	18	30	46	51	65
Inventory Days	66	54	58	82	73	89	107	80	128	157
Payable Days	52	57	69	93	67	54	68	59	92	101

SMS Pharmaceuticals Ltd Stock News

SMS Pharmaceuticals Ltd FAQs

What is the share price of SMS Pharmaceuticals?

Company share prices are keep on changing according to the market conditions. The closing price of SMS Pharmaceuticals on 18-Apr-2024 12:35 is ₹207.5.

What is the market cap of SMS Pharmaceuticals?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Apr-2024 12:35 the market cap of SMS Pharmaceuticals stood at ₹1,766.3.

What is the P/E ratio of SMS Pharmaceuticals?

The latest P/E ratio of SMS Pharmaceuticals as of 18-Apr-2024 12:35 is 42.48.

What is the P/B ratio of SMS Pharmaceuticals?

The latest P/B ratio of SMS Pharmaceuticals as of 18-Apr-2024 12:35 is 3.36.

What is the 52-week high and low of SMS Pharmaceuticals?

The 52-week high of SMS Pharmaceuticals is ₹217.6 and the 52-week low is ₹65.00.

What is the TTM revenue of SMS Pharmaceuticals?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of SMS Pharmaceuticals is ₹612.9 ( Cr.) .

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd. is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities. What started off as a single facility single product manufacturing company in 1990 grew to be a multi location group having product list spreading across an array of therapeutic segments. SMS is currently a listed company having ever appreciating international and domestic customer base. Having six multi product facilities in operation, one under development, and two research centers, SMS has truly graduated in to big league with more than 600 employees working for it.

SMS Pharmaceuticals is an integrated pharma company with business presence in over 70 countries.

SMS is focused on API manufacturing and is the single largest producer of anti ulcer products and is renowned among the clientele for the excellent quality of product and customer service.

The company is diversifying into CRAMS by creating research and manufacturing facilities bettering the requirements of the regulatory markets to appeal to international clientele.

SMS is venturing into highly specialized oncology segment by building first of its kind dedicated oncology API and formulations manufacturing facility in Andhra Pradesh to target the niche market segments.

Merger of Sreenivasa Pharma Private Ltd with SMS Pharmaceuticals Ltd has given a new boost to the company, SMS Pharma has also completed the takeover of Plant Organics.

Recently SMS has established new state of art corporate research center with ultramodern facilities encompassing the whole gamut of research activity viz. from product conception to development, scaling up and DMF preparation. This is supported by well equipped analytical wing and a fully functional pilot plant. This new facility will enhance our existing offerings from a contract research and custom synthesis point of view.

R&D at SMS drives the companyâ€™s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.

SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.

Product range of the company includes:

API and Intermediates
Cytotoxic Solid Dose, Sterile Cytotoxic Liquid, and Lyophilized Products
Bio Products
Inorganic Products
Nutraceuticals

Different divisions of the company:

Manufacturing :SMS Pharmaceuticals Ltd. is one of the leading pharmaceutical manufacturing companies in India with world-class facilities with a wide range of process equipment fully compliant with WHO GMP standards.SMS has over the years developed tremendous manufacturing facilities to suit its style of operations and to meet the requirements of USFDA and other regulatory markets. A total of 6 facilities are being presently operated and one is under construction.
Research and development :R&D at SMS drives the companyâ€™s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.SMS research team now comprises of about 100 scientists with expertise in process research, analytical research and scale up. A dedicated project management team handles costing, administration, purchase, and project monitoring. R&D capabilities of the company span across reaction technologies, organic compound categories, and novel catalytic systems. This center is capable of delivering top notch contract research modules to international clientele.

Achievements/ recognition :

SMS was given the export house status in the year 1997-98.
Awarded the Prestigious ' Pandit Jawaharlal Nehru Silver Rolling Trophy' for the best productivity effort in the state.
Became the single largest producer of Ranitidine Hydrochloride in the World.
One of the leading export houses exporting to more than 70 countries worldwide.
WHO-GMP approved API manufacturing facilities in India (2 more to be operational soon).
Achieved ISO 9001 certification for Units at Khazipally and Bollaram.
Awarded the prestigious US GCNC Green chemistry award.
Successfull FDA audits in 2004 and 2008 at our Bachupally unit.
Proven expertise in low cost process routes, commercialization & manufacturing.
Over 21 process patents and 72 regulatory filings.
Successful execution of contract research and manufacturing assignments.
CRISIL renews SMS Pharma's SME 1 rating for FY 09-10.
Recieved 'Best Industrial Productivity Effort in the State' silver rolling trophy.

Future plan:

SMS is building an ultra modern API manufacturing facility near Vizag on the eastern coast of India to cater to in house production needs and also for the emerging contract manufacturing business.